COST-EFFECTIVENESS OF SIMVASTATIN COMPARED WITH ATORVASTATIN FOR LOW-DENSITY LIPOLIPOTIEN CHOLESTEROL (LDL-C) IN DIABETES PATIENTS WITH DYSLIPIDEMIA AT A GENERAL HOSPITAL, NORTHEAST OF THAILAND

摘要: Problem statement: Statins are effective medicine for lowering LDL-C in dyslipidemia; 3 statinsin a general hospital formulary are simvastatin, atorvastatin, and rosuvastatin. Even simvastatin is in the Thai National Drug List 2004 (NDL) and its bioequivalent, generic products are available, but branded atorvastatin and rosuvastatin still are prescribed at high cost to the patient. Economic evaluation is needed to support the Pharmacy and Therapeutic Committee (PTC) in promoting rational use of medicine.Objective: To analyse cost effectiveness of simvastatin compared with atorvastatin for lowering LDL-C in diabetes patients with dyslipidemia. Design: A 6-month follow up, retrospective cohort study was performed during the period July 1–December 31, 2006. Samples were also included from May and June 2006. Two components of operating cost for the 6-month treatment, including labor cost and material cost …